New study and promising results from the first clinical trial in patients provide novel insights and new hope for one of the deadliest of cancers. Gastric cancer remains a formidable adversary, ...

Eli Lilly and Co. has received the Federal Drug Administration’s breakthrough therapy designation for a drug in development ...

Gastric cancer remains a formidable adversary, ranking as the fifth most common cancer and the third-leading cause of cancer-related deaths worldwide, with over 1,000,000 new cases and close to ...

Gastric cancers commonly spread to the peritoneum. Its presence significantly alters patient prognosis and treatment-intent; however, current methods of peritoneal staging are inaccurate. Peritoneal ...

Sofetabart mipitecan is an antibody-drug conjugate consisting of an Fc-silent, folate receptor alpha specific monoclonal antibody attached to an exatecan payload.

Validity of the Patient-Reported Outcome Measurement Information System (PROMIS) Sexual Interest and Satisfaction Measures in Men Following Radical Prostatectomy Compared with CRSa, CRS-HIPEC improved ...

Image Caption: Proteomic alterations in post-NACT OCPM tissues. Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the ...